{"entity":{"id":"nct01582672","kind":"trial","name":"Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma","aka":[],"tldr":"A phase 3 trial of Rocapuldencel-T run by Argos Therapeutics, terminated.","summary":"Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma is a phase 3 interventional study registered as NCT01582672 by Argos Therapeutics, with 462 participants enrolled, started 2012-11. Conditions recorded: Advanced Renal Cell Carcinoma, Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma. Interventions recorded: Standard Treatment and AGS-003.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT01582672","url":"https://clinicaltrials.gov/study/NCT01582672"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["rocapuldencel-t"],"companies":["argos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01582672","phase":"3","setting":"An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)","sponsor":"Argos Therapeutics","enrolled":462,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01582672/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"rocapuldencel-t","kind":"drug","name":"Rocapuldencel-T","route":"/drugs/rocapuldencel-t/"}],"company":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/"}]}}